Kezar Life Sciences (KZR) Competitors $4.11 -0.21 (-4.86%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$4.18 +0.07 (+1.82%) As of 04/15/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KZR vs. GLSI, IKT, PRQR, FDMT, NMRA, LRMR, NGNE, SCPH, OGI, and ADCTShould you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Greenwich LifeSciences (GLSI), Inhibikase Therapeutics (IKT), ProQR Therapeutics (PRQR), 4D Molecular Therapeutics (FDMT), Neumora Therapeutics (NMRA), Larimar Therapeutics (LRMR), Neurogene (NGNE), scPharmaceuticals (SCPH), Organigram (OGI), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. Kezar Life Sciences vs. Greenwich LifeSciences Inhibikase Therapeutics ProQR Therapeutics 4D Molecular Therapeutics Neumora Therapeutics Larimar Therapeutics Neurogene scPharmaceuticals Organigram ADC Therapeutics Greenwich LifeSciences (NASDAQ:GLSI) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability. Does the MarketBeat Community believe in GLSI or KZR? Kezar Life Sciences received 129 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 57.08% of users gave Kezar Life Sciences an outperform vote while only 44.44% of users gave Greenwich LifeSciences an outperform vote. CompanyUnderperformOutperformGreenwich LifeSciencesOutperform Votes844.44% Underperform Votes1055.56% Kezar Life SciencesOutperform Votes13757.08% Underperform Votes10342.92% Do institutionals & insiders have more ownership in GLSI or KZR? 4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 51.7% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 9.3% of Kezar Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, GLSI or KZR? Greenwich LifeSciences has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Is GLSI or KZR more profitable? Kezar Life Sciences' return on equity of -54.95% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Greenwich LifeSciencesN/A -185.12% -164.27% Kezar Life Sciences N/A -54.95%-46.11% Which has stronger valuation and earnings, GLSI or KZR? Greenwich LifeSciences has higher earnings, but lower revenue than Kezar Life Sciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGreenwich LifeSciencesN/AN/A-$8.89M-$0.80-11.19Kezar Life Sciences$7M4.29-$101.87M-$11.55-0.36 Does the media favor GLSI or KZR? In the previous week, Greenwich LifeSciences had 4 more articles in the media than Kezar Life Sciences. MarketBeat recorded 5 mentions for Greenwich LifeSciences and 1 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 1.89 beat Greenwich LifeSciences' score of 0.80 indicating that Kezar Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Greenwich LifeSciences Positive Kezar Life Sciences Very Positive Do analysts prefer GLSI or KZR? Greenwich LifeSciences presently has a consensus price target of $38.00, indicating a potential upside of 324.58%. Kezar Life Sciences has a consensus price target of $39.50, indicating a potential upside of 861.07%. Given Kezar Life Sciences' higher probable upside, analysts clearly believe Kezar Life Sciences is more favorable than Greenwich LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryKezar Life Sciences beats Greenwich LifeSciences on 9 of the 15 factors compared between the two stocks. Remove Ads Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZR vs. The Competition Export to ExcelMetricKezar Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.03M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.316.8121.7017.82Price / Sales4.29225.96377.7294.61Price / CashN/A65.6738.1534.64Price / Book0.165.866.464.00Net Income-$101.87M$141.86M$3.20B$247.23M7 Day Performance0.24%4.38%2.77%1.44%1 Month Performance-29.98%-12.76%-8.60%-6.26%1 Year Performance-47.52%-11.13%10.40%0.59% Kezar Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZRKezar Life Sciences4.2509 of 5 stars$4.11-4.9%$39.50+861.1%-49.2%$30.03M$7M-0.3160Positive NewsGLSIGreenwich LifeSciences1.9672 of 5 stars$9.59+8.6%$38.00+296.2%-37.2%$126.06MN/A-11.993Earnings ReportUpcoming EarningsNews CoverageHigh Trading VolumeIKTInhibikase Therapeutics1.4363 of 5 stars$1.68-8.7%$6.50+286.9%-13.4%$124.90M$260,000.00-0.636Gap DownPRQRProQR Therapeutics2.169 of 5 stars$1.17-0.8%$9.50+712.0%-41.8%$123.10M$18.91M-3.66180Short Interest ↓News CoverageFDMT4D Molecular Therapeutics2.5766 of 5 stars$2.65-4.3%$26.71+908.1%-88.2%$122.70M$37,000.00-0.93120Positive NewsGap DownNMRANeumora Therapeutics3.1613 of 5 stars$0.75+2.3%$9.29+1,132.8%-94.1%$122.00MN/A-0.40108LRMRLarimar Therapeutics3.2832 of 5 stars$1.87-4.6%$19.63+949.5%-74.2%$119.73MN/A-1.6330Positive NewsNGNENeurogene2.1156 of 5 stars$7.86-10.6%$53.00+574.3%-69.7%$117.35M$925,000.00-1.8490Analyst ForecastGap UpHigh Trading VolumeSCPHscPharmaceuticals3.7527 of 5 stars$2.33+0.4%$14.00+500.9%-45.7%$117.16M$36.33M-1.2330Short Interest ↓OGIOrganigram0.6678 of 5 stars$0.92-2.7%N/A-44.7%$116.74M$166.12M-2.43860Positive NewsADCTADC Therapeutics2.131 of 5 stars$1.17-1.3%$7.75+565.2%-72.6%$115.43M$70.84M-0.49310 Remove Ads Related Companies and Tools Related Companies GLSI Competitors IKT Competitors PRQR Competitors FDMT Competitors NMRA Competitors LRMR Competitors NGNE Competitors SCPH Competitors OGI Competitors ADCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZR) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMusk's panic move: What the world's richest man fears is comingWhether you have modest savings of $10,000 or substantial wealth of $10 million, this information could determ...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KZR Stock Free KZR Stock Alerts